著者

崔 吉道

出版者

日本DDS学会

雑誌

Drug Delivery System (ISSN:09135006)

巻号頁・発行日

vol.21, no.2, pp.111-118, 2006 (Released:2006-08-18)

参考文献数

59

---

薬物トランスポーターの詳細で包括的な情報がデータベース化されている. また遺伝子バンクの整備が進み, トランスポーター遺伝子発現系を利用することで, 開発中の化合物のトランスポーターに対する認識性を解析することが可能である. 近年, トランスポーターの発現分布や基質認識特性を考慮したドラッグデザインやプロドラッグ化が注目されている.本稿では, 薬物の体内動態制御に関わるトランスポーターについて例をあげて紹介し, トランスポーターを利用した臓器選択的DDSにおいて考慮すべき諸問題について考察する.

著者

中川 祐紀子 鈴木 拓也 志村 裕介 菅 幸生 嶋田 努 崔 吉道

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.43, no.1, pp.26-33, 2017-01-10 (Released:2018-01-10)

参考文献数

10

被引用文献数

2 3

---

The ward pharmacist received a report from ward nursing staff that an aggregation formed when lansoprazole OD tablets and ground levofloxacin tablets were suspended simultaneously in water. In this study, we elucidated the factors of aggregation focusing on additives, the main drug, and pH in suspension, and also considered ways of preventing the aggregation. To elucidate the contribution of additives in levofloxacin tablets, drugs containing similar additives to those of levofloxacin tablets were suspended with lansoprazole OD tablets in water, but no aggregation was observed. Levofloxacin hydrate intravenous drip infusion (pH 4.8) did not form an aggregation with lansoprazole OD tablets, meanwhile levofloxacin hydrate intravenous drip infusion adjusted to pH 7.3 and levofloxacin hydrate solution adjusted to pH 7.3 formed an aggregation with lansoprazole OD tablets. When lansoprazole OD tablets and ground levofloxacin tablets were suspended in a buffer solution of pH 5.0, pH 6.0, and pH 7.0, no aggregation was observed in a buffer solution of pH 5.0. When generic lansoprazole OD tablets and generic lansoprazole capsules were suspended with levofloxacin tablets in water, aggregation was also observed. On the other hand, the aggregation of lansoprazole OD tablets was not observed when lansoprazole OD tablets and levofloxacin tablets were suspended in apple juice. According to the above results, factors related to the formation of the aggregation were involved in the preparation of lansoprazole, levofloxacin hydrate, and around pH 6.0, and the suspending of lansoprazole OD tablets and levofloxacin tablets simultaneously in acidic drinks such as apple juice is means of avoiding the aggregation.

著者

山本 奈歩 堀 祐貴 髙廣 理佳子 菅 幸生 嶋田 努 崔 吉道

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.45, no.3, pp.127-134, 2019-03-10 (Released:2020-03-11)

参考文献数

19

被引用文献数

2

---

Albumin-bound paclitaxel (nab-PTX) plus gemcitabine (GEM) therapy (GnP) is often administered to patients with unresectable metastatic pancreatic cancer. However, chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect. In this study, we investigated the risk factors for CIPN in patients who were receiving GnP therapy for pancreatic cancer at our hospital and had a history of prior chemotherapy. The patientsʼ background, laboratory data, previous treatment history, concomitant medication, dose and number of medicines, and occurrence status of side effects were examined. The frequency of CIPN in patients receiving GnP therapy at our hospital was 72%. Multiple logistic regression analysis revealed that a history of FOLFIRINOX therapy (FFX), including oxaliplatin (L-OHP) administration, (odds rate: 3.864, 95% CI: 1.160-12.868) and female sex (odds rate: 3.673, 95% CI: 1.102-12.242) were risk factors for CIPN. In addition, the severity of CIPN was significantly higher in patients with a history of FFX administration (P = 0.011). Further, the cumulative dose and the administration period of nab-PTX until the onset of CIPN were significantly lower in patients with a history of FFX administration (P = 0.016, P = 0.004, respectively). We suggest that special care in monitoring GnP therapy is necessary in female patients with a history of FFX administration.

著者

伊藤 智代 中出 順也 嶋田 努 崔 吉道

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.44, no.8, pp.403-409, 2018-08-10 (Released:2019-08-14)

参考文献数

12

---

FOLFIRINOX is a novel chemotherapy that has been approved for the treatment of advanced pancreatic adenocarcinoma. In comparison with the conventional gemcitabine single agent therapy, FOLFIRINOX is advanced for objective responses, progression-free survival, and median overall survival. Cholinergic syndromes are frequently observed in patients receiving FOLFIRINOX and have been suggested to occur due to the inhibition of acetylcholinesterase by irinotecan (CPT-11). However, no research has been performed on the incidence and risk factors of cholinergic syndromes under FOLFIRINOX. This study aimed to evaluate the incidence and risk factors of cholinergic syndromes induced by FOLFIRINOX in retrospective investigation. Forty-eight patients who were treated with the first cycle of FOLFIRINOX were analyzed and 33 (68.8%) of those experienced cholinergic syndromes including diaphoresis (50.0%), acute diarrhea (33.3%), abdominal pain (29.2%), dysarthria (8.3%), and one for each case of bradycardia, nasal flow, miosis and numbness in the hands. Diaphoresis was experienced more frequently in younger patients (P = 0.029). Other characteristics of patients had no significant relationship with the induction of cholinergic syndrome; sex, stage of cancer, performance status, prior chemotherapy, dose of CPT-11, use of opioid, use of NSAIDs and/or acetaminophen and UGT1A1 genotype. This study indicated for the first time that cholinergic syndromes are observed in almost 70% of patients treated with FOLFIRINOX, and it might be due to the combination of CPT-11 and oxaliplatin. Since cholinergic syndromes can deteriorate the quality of life, patients should be monitored carefully regardless of their characteristics under FOLFIRINOX.